KR20200124892A - Composition comprising extracts of chrysanthyum indicum for improving sleep disturbance caused by caffeine - Google Patents

Abstract

An object of the present invention relates to a food composition and a pharmaceutical composition for ameliorating sleep disorders caused by caffeine, comprising a Chrysanthemum indicum extract.

Description

A composition for improving sleep disorders caused by caffeine containing Gamguk extract {COMPOSITION COMPRISING EXTRACTS OF CHRYSANTHYUM INDICUM FOR IMPROVING SLEEP DISTURBANCE CAUSED BY CAFFEINE}

An object of the present invention relates to a food composition and a pharmaceutical composition for improving sleep disorders caused by caffeine, comprising a Gamguk extract.

Caffeine has been consumed for a long time around the world and is an ingredient in various types of foods such as coffee, tea, soft drinks, chocolate, etc. that many people enjoy, as well as nutrients and tonics and other medicines. Caffeine consumption can lead to negative withdrawal and addiction symptoms. In addition, intake of caffeine in an appropriate amount is known to have beneficial effects on the body, such as releasing fatigue accumulated in our body, clearing the mind, and removing body wastes through diuretic action. It causes side effects such as excitement and insomnia, and can lead to caffeine addiction if consumed continuously. In particular, vulnerable groups such as children and pregnant women may have more severe side effects from caffeine intake than adults, so caution is required when eating caffeine-containing foods.

On the other hand, sleep accounts for 1/3 of human lifespan and is the most fundamental and essential physiological phenomenon, and is a very important factor in maintaining health and mental stability. Chronic sleep deprivation and disorders negatively affect overall physical and mental health, including cardiovascular disease, high blood pressure, memory, learning, metabolic regulation, weight, immunity, cancer resistance, diabetes, safety accidents and mood.

Drugs such as benzodiazepines and serotonins are used as drugs to treat sleep disorders such as insomnia, but when these drugs are taken for a long time, side effects that form resistance to drugs and drug dependence occur, resulting in initial or temporary insomnia. There are some aspects that are not suitable for use with those who appeal. Therefore, in the case of people who need to take sleeping pills for a long time, there is an increasing need for sleep aids and/or sleep quality improvement agents derived from natural materials as a substitute for this.

In addition, as interest in sleep-promoting health functional foods increases, development of health functional foods that can improve the quality of sleep of the general public as well as medicines that can treat or prevent sleep disorders such as insomnia is more demanded. .

Korean Patent Registration No. 10-1207781

It is an object of the present invention to provide a food composition for improving sleep disorders caused by caffeine, comprising an extract of Gamguk.

Another object of the present invention is to provide a pharmaceutical composition for preventing and treating sleep disorders caused by caffeine, comprising an extract of Gamguk.

Terms used in the present specification have selected general terms that are currently widely used as possible while considering functions in the present invention, but this may vary depending on the intention or precedent of a technician working in the field, the emergence of new technologies, and the like. In addition, in certain cases, there are terms arbitrarily selected by the applicant, and in this case, the meaning of the terms will be described in detail in the description of the corresponding invention. Therefore, the terms used in the present invention should be defined based on the meaning of the term and the overall contents of the present invention, not a simple name of the term.

Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related technology, and should not be interpreted as an ideal or excessively formal meaning unless explicitly defined in this application. Does not.

One aspect of the present invention for achieving the above object relates to a food composition for improving sleep disorders caused by caffeine, including a Gamguk extract.

In the present invention, " Chrysanthemum indicum L." is a perennial plant belonging to the chrysanthemum family (菊花科, Asteraceae) and is also referred to as Hwangguk (黃菊). It grows mainly in the mountains, and in October, flowers are dried and drunk in alcohol, and young leaves are used as herbs. Gamguk is known to lighten the body, do not get old, make long life, increase muscle bones, see bone marrow, brighten eyes, heal punghyeon headache, and use it when drinking alcohol and not awakening.

Specifically, the Gamguk extract is ₁ selected from the group consisting of water, C ₁ to C ₄ anhydrous or lower alcohol, a mixed solvent of water and lower alcohol, acetone, 1,3-butylene glycol, ethyl acetate, and chloroform It may be obtained by extraction with one or more species alone or a mixed solvent, but is not limited thereto, and any solvent known in the art may be used.

In addition, the "extract" is formed using the extract itself and the extract, such as the extract of Gamguk, as well as the dilution or concentrate of the extract, a dried product obtained by drying the extract, a preparation or purified product of the extract, or a mixture thereof. Includes extracts of all possible formulations.

The extract of the present invention may be extracted from natural, hybrid or variant plants of the Gamguk, and may also be extracted from plant tissue culture.

The method of extracting the extract of the present invention is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, and the like, which may be performed alone or in combination of two or more methods.

In the present invention, the extract extracted with hot water or cold needle is filtered to remove floating solid particles, for example, nylon, etc. to filter the particles, or after filtration using a freeze filtration method, etc., or use as such, or freeze drying, hot air drying, It can be used after drying by spray drying or the like.

In one embodiment of the present invention, a Gamguk extract was obtained through a hot water extraction method, and it was confirmed that the Gamguk extract can improve sleep disorders by mitigating the decrease in nerve activity and sleep time caused by caffeine.

In the present invention, "sleep disorder" includes all disorders that may be pathological during sleep, even if the physical function is normal during awakening, and is a sleep disorder caused by stress, health conditions, pain, medication, jet lag, or noise. Insomnia, sleep respiration disorder, hypersomnia, circadian rhythm sleep disorder, abnormal exercise during sleep, parasomnia, etc. may be included. The sleep disorder is widely used as meaning any and all types and grades of sleep loss. The sleep disorder may persist acutely or chronically, and specifically, may be a sleep disorder caused by caffeine.

More specifically, the sleep disorder may be caffeine-induced insomnia or circadian rhythm sleep disorders.

In the present invention, "insomnia" refers to a state where it is difficult to fall asleep, awakening frequently while sleeping, or showing unpleasant symptoms alone or in combination when waking up in the morning. It is known that the insomnia may occur when caffeine is taken, and the composition of the present invention has been confirmed to improve the reduction of sleep time caused by caffeine (FIG. 6), and can be used for improving the insomnia.

In the present invention, “circadian rhythm sleep disorders” are disorders that occur when a problem occurs in the body organs in charge of the circadian rhythm or the alignment between the internal circadian rhythm and external factors is broken. Representative diseases include delayed or progressive sleep phase syndrome, and may occur as the biological cycle changes due to the influence of physiological or neurological activity by compounds such as caffeine. It was confirmed that the composition of the present invention can alleviate the neural activity caused by caffeine (FIG. 4), and it can improve the circadian rhythm sleep disorder according to the change in the circadian cycle caused by caffeine.

In addition, specifically, the form of the food may be coffee, but is not limited thereto. The coffee may be ground coffee or instant coffee, and the form of the coffee is not particularly limited. In addition, specifically, the coffee may include no-caffeine coffee.

For coffee beans, you can use beans from Jamaica Blue Mountain, Indonesia Toraja, Colombia Souprimo, Guatemala Antigua, Kenya Arabica, Brazil Santos, Ethiopia Mocha Yegachev. These beans can be used by drying the green beans and grinding them after roasting, and roasting is by heating the green beans and roasting them.By applying heat to the green coffee beans, it causes physical and chemical changes in the internal structure of the green beans to determine the unique taste and aroma of coffee. It is a processing treatment.

Instant coffee may further contain sugars and fats and oils to the coffee beans. At this time, the saccharide is any one selected from white sugar, glucose, dextrin, fructose, oligosaccharide, propolis, trehalose, sorbitol, xylitol, mannirol, mantyrol, ramnirol, inosyrol, erythrolol, paratinose, and quersirol You can use the above. In addition, the fat or oil may be used any one or more selected from powdered milk, skim milk powder, and plant ingredients.

Coffee containing the extract of Gamguk of the present invention not only prevents sleep disturbance, which is one of the side effects caused by coffee, but also inhibits neurological hyperactivity caused by an overdose of caffeine. In particular, by being added to or included in coffee, the Gamguk extract does not alter the original taste of coffee, and acts competitively with caffeine, thereby minimizing the insomnia effect that may be caused by caffeine.

Foods to which the Gamguk extract of the present invention can be added include not only coffee, but also sausage, meat, bread, chocolate, snacks, candy, confectionery, ramen, pizza, other noodles, gum, dairy products including ice cream, various soups, Beverages, teas, beverages, alcoholic beverages and vitamin complexes. When formulated as a beverage, the liquid component added in addition to the extract of the present invention is not limited thereto, but may contain various flavoring agents or natural carbohydrates as an additional component, such as a conventional beverage. The natural carbohydrates described above are monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.) and polysaccharides (e.g., common sugars such as dextrin, cyclodextrin, etc.), and xylitol, sorbitol. And sugar alcohols such as erythritol.

The type of food may be a food additive, and the food additive refers to a substance used by a method such as adding, mixing, infiltrating or adding to food for the preparation, processing, or preservation of food. The food additives include natural products and synthetic products, and can be classified according to functions and uses. Currently, 370 kinds of chemical synthetic products and 50 kinds of natural additives are approved as food additives in Korea. Depending on the purpose, preservatives, fungicides, antioxidants, coloring agents, coloring agents, bleaching agents, seasonings, sweeteners, flavoring agents, expanding agents, strengthening agents, and improving agents , Emulsifiers, thickeners and stabilizers, coating agents, gum base agents, defoaming agents, solvents, releasing agents, insect repellents, quality improvers and other additives for food manufacturing.

The form of the food additive may include a powder, granule, tablet, capsule or liquid form, but is not limited thereto.

In addition, the type of food may specifically be a health functional food. The health functional foods include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, organic acids, protective colloidal growth It may contain an agent, a pH adjuster, a stabilizer, a preservative, glycerin, alcohol, a carbonation agent used in carbonated beverages, and the like. In addition, the health functional food of the present invention may contain pulp for the manufacture of fruit and vegetable beverages. These components may be used alone or in combination, and the ratio of these additives is generally selected from 0.001 to 50 parts by weight per total weight of the composition, but is not limited thereto.

The health functional food is a food that emphasizes the biological regulation function of food, and is a food that has added value to act and express it for a specific purpose by using physical, biochemical, and bioengineering methods. Ingredients of these health functional foods are designed and processed to fully exert the body's control functions related to body defense, regulation of body rhythm, prevention and recovery of diseases to the living body, and food additives, sweeteners, or functional foods acceptable as foods. It may contain raw materials.

When using the Gamguk extract of the present invention as a health functional food (or a health functional beverage additive), the Gamguk extract may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the Gamguk extract may be appropriately determined according to the purpose of use (prevention, health or improvement, therapeutic treatment).

Another aspect of the present invention relates to a pharmaceutical composition for preventing or treating sleep disorders caused by caffeine, comprising an extract of Gamguk. Specifically, the sleep disorder may be caffeine-induced insomnia or circadian rhythm sleep disorders.

“Sleep disorder”, “insomnia”, and “circadian rhythm sleep disorder” are as described above.

For administration, the pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier, excipient, or diluent in addition to the extract of the present invention. The carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oils.

In addition, the pharmaceutical composition of the present invention can be applied in any formulation, and more specifically, may be an oral formulation. The parenteral formulation may be in the form of a spray such as injection, application, or aerosol.

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.

Another aspect of the present invention relates to a method of treating sleep disorders, comprising administering a pharmaceutical composition comprising an extract of Gamguk to an individual in need thereof in a pharmaceutically effective amount. Specifically, the sleep disorder may be caffeine-induced insomnia or circadian rhythm sleep disorder.

“Sleep disorder”, “insomnia”, and “circadian rhythm sleep disorder” are as described above.

In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the patient's sexually transmitted disease, age, type of disease, severity, drug Activity, sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including concurrent drugs, and other factors well known in the medical field.

The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with a conventional therapeutic agent. In addition, the pharmaceutical composition of the present invention may be administered single or multiple. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and can be easily determined by a person skilled in the art.

The term "subject" of the present invention includes an animal or human having a sleep disorder whose symptoms can be improved by administration of the pharmaceutical composition according to the present invention. By administering the therapeutic composition according to the present invention to an individual, sleep disorders can be effectively prevented and treated.

The term "administration" of the present invention means introducing a predetermined substance to humans or animals by any suitable method, and the route of administration of the therapeutic composition according to the present invention is through any general route as long as it can reach the target tissue. It can be administered orally or parenterally. In addition, the therapeutic composition according to the present invention can be administered by any device capable of moving the active ingredient to target cells.

The preferred dosage of the pharmaceutical composition according to the present invention varies depending on the condition and weight of the patient, the degree of the disease, the drug form, the route and duration of administration, but may be appropriately selected by those skilled in the art.

The composition of the present invention has the effect of pacifying excessive neurological activity caused by caffeine and improving sleep disorders at the same time. In particular, as it can inhibit the continuous action of caffeine beyond the effect of inhibiting the neurological activity of caffeine in a short time, , It can be widely used for improving sleep disorders while stabilizing the nerve activity induced by caffeine.

The effects of the present invention are not limited to the above effects, and should be understood to include all effects that can be deduced from the configuration of the invention described in the detailed description or claims of the present invention.

1 shows a hippocampal tissue section culture process.
Figure 2 shows a microelectrode array (MEA) setting process of the hippocampal tissue.
3 shows a microelectrode array (MEA) experimental protocol (A) and a spike detection process (B) using a band pass filter.
Figure 4 shows the results confirming that the nerve activity by caffeine was alleviated when treated with Gamguk extract (A: neurological activity during caffeine treatment, B: neurological activity during caffeine and Gamguk extract treatment, C: caffeine alone treatment and caffeine and Gamguk Comparison of neuronal activity before washing in extract treatment, D: Comparison of neuronal activity after washing in caffeine alone treatment and caffeine and Gamguk extract treatment).
5 shows an experimental process of oral administration and recording to SD rats for measuring sleep time (A: oral administration process to SD rats, B: recording process for measuring sleep time).
Figure 6 shows the results of confirming that the sleep time was recovered during the treatment of Gamguk extract (A: caffeine alone treatment, B: caffeine and Gamguk extract treatment).

Hereinafter, the present invention will be described in detail by examples. However, the following examples are only illustrative of the present invention, and the present invention is not limited by the following examples.

Example 1. Preparation of Gamguk Extract

10 times (w/v) of distilled water was added to 50 g of Gamguk (Gio Herb Co., Yangju, Korea), followed by hot water extraction at 121°C for 40 minutes. Whatman No. 1 Filtered using filter paper (Whatman International Ltd., Maidstone, UK), and the filtered extract was concentrated for 5 hours at 40 ℃ using a concentrator (Eyela Co., Tokyo, Japan). The concentrated extract was freeze-dried for 7 days at -70°C and 5 mTorr with a freeze dryer (Ilsin Bio Co., Yangju., Korea), then pulverized with a grinder (Ilsin Bio Co., Yangju., Korea) for experiments. Was used. The yield is 11.4% when hot water extraction of Gamguk is performed through the above process.

Raw material (g) Extract (g) Yield (%; extract/raw material) Secret country 50 5.7 11.4

Experimental Example 1. Measurement of nerve activity

1-1. Hippocampal organotypic slice culture (HOSC)

The method of organotypic culturing of the brain hippocampus slices using a thin film has already used a commonly used method. Specifically, the cerebral hippocampus was excised from Sprague Dawley white young rats (Orientbio Co., Seungnam, Korea) between 5 and 7 days old and sectioned to a thickness of 350 μm using a tissue slicer (Mickle Laboratory Engineering Co., UK). After placing 5 to 6 pieces in a thin film insert (Millicell-CM; Millipore, MA) with a 0.4μm hole, put it in a 6-well plate (SPL Life Sciences Co., Korea) and 5% CO at 36°C. ₂ (Dong-A Co., Seoul, Korea) was cultured in an incubator maintained. Culture solution (MEM; Welgene, Gyeongsan, South Korea), 20mM HEPES (Sigma, St. Louis, Mo, USA), 25% Hank's balanced salt solution (HBSS; Welgene, Gyeongsan, South Korea), 6 g/L D-glucose (Sigma, St. Louis, Mo, USA), 1mM L-glutamine (Sigma, St. Louis, Mo, USA), 25% horse serum (Welgene, Gyeongsan, South Korea) and 1% penicillin-streptomycin (Gibco BRL, USA), pH=7.1) was changed once every two days, and the culture period was 12 to 14 days, which was used in subsequent experiments (Fig. 1).

1-2. Migration of cerebral hippocampal tissue cultured with MEA probes

After carefully separating the cerebral hippocampal section cultured using a pin from the culture thin film insert, it was coated with 0.01% polyethyleneimine (polyethylenimine, Sigma, St. Louis, Mo, USA) and coated with 10 μm diameter and 100 μm spacing. It was placed on an electro-electrode array (MEA; Multi Channel Systems, Germany). Sections are sterile artificial spinal cord solution (aCSF; 114 mM NaCl, 26 mM NaHCO ₃ , 10 mM glucose, 3 mM KCl, 2 mM CaCl ₂ , 1 mM MgCl ₂ , 20 mM HEPES, pH=7.4, Sigma, Louis, Mo , USA) for 15 minutes, 5% CO ₂ and 95% O ₂ mixed gas (Dong-A Co., Seoul, Korea) was injected and stabilized at 33 °C. After that, the MEA including the brain hippocampus was mounted on the amplification device of MEA1060 (Multi Channel Systems Inc., Reutlingen, Germany), and the artificial spinal cord solution in the MEA was grounded with Ag/AgCl. During the subsequent experiment, the artificial spinal cord solution into which 5% CO ₂ and 95% O ₂ mixed gas were added was perfused at a rate of 3 mL/min, and the MEA and the artificial spinal cord solution were maintained at 33°C (Fig. 2). ).

1-3. Nerve activity measurement

Stabilized hippocampal tissue was recorded for 3 minutes, and thereafter, artificial cerebrospinal fluid containing 1 mM caffeine (Sigma, St. Louis, Mo, USA) or artificial cerebrospinal fluid containing 1 mM caffeine and 200 μg/ml of Gamguk extract. The cerebrospinal fluid was perfused under the same conditions for 20 minutes, and then recorded for 3 minutes. After washing for 20 minutes only with artificial cerebrospinal fluid, the data was recorded for 3 minutes to obtain data for a total of 9 minutes.

MEA with hippocampal tissue reads data at a sampling rate of 25 kHz for each channel through a total of 60 channels, and is recorded through a computer using MC_Rack and MC_Data Tool (Multi Channel Systems, GmbH) software. A band pass filter of 4 steps was used to extract meaningful spikes from all recorded signals, and the equation is as follows.

[Equation 1]

In the above equation, X represents an effective value (RMS) for noise, and ĸ is a factor that determines each threshold. Here, the threshold was constructed with a total of 3 factors (0.6, 1 and 3). When the ĸ value is more than 0.6, a meaningful spike is used, and the threshold level at this time is -21.63 μV. This process was performed using a MATLAB (Mathworks Inc., Natick, Massachusetts, USA) program for all 60 channels (FIG. 3).

As a result, as shown in Figure 4, it was confirmed that the nerve activity caused by caffeine was alleviated when the extract of Gamguk was treated.

Specifically, when caffeine was treated, neuronal activity was increased, and even after washing after caffeine treatment, the action of caffeine continued to increase neuronal activity by 200% or more (FIG. 4A). On the other hand, when caffeine and Gamguk extract were treated together, the degree of neuronal activity was significantly reduced compared to when caffeine was treated alone. Unlike caffeine alone treatment, the neuronal activity did not show a continuous increase even after washing. It was confirmed that it was maintained without increasing the enemy (Fig. 4B). It was confirmed that when caffeine was treated alone and when caffeine and Gamguk extract were treated together, a remarkable neuronal activity reduction effect was observed when the Gamguk extract was treated even before washing and after washing for each (Fig. 4C and FIG. 4D). In particular, the activity of caffeine in the nerves is increased even after washing after treatment with caffeine, which indicates that the active action of caffeine on the nerves does not appear briefly in a short time, but rather continues. Gamguk extract of the present invention exhibited the effect of reducing neuronal activity by suppressing the effect of caffeine which is continuously increased as described above.

Experimental Example 2. Measurement of sleep time

2-1. Experimental animals

Sprague Dawley rat 6 weeks old was selected as the experimental animal, and it was purchased from Orient Bio (Seongnam, Korea). In order to keep the experimental environment constant, one experimental animal per cage was put and reared. The experimental animals went through an adaptation period for one day in an environment where 25℃, 50% humidity, and lighting (12 hours light/dark) were automatically maintained, and drinking water and diet were supplied freely. All procedures followed the policy of Kyunghee University's Laboratory Animal Ethics Committee and regulations related to animal testing (IRB approval number: KHUASP(SE)-17-039).

2-2. Sleep time measurement

The experiment was performed by dividing 15 SD rats into 3 groups (n=5). Water was orally administered to Group 1, caffeine (20mg/Kg) was orally administered to Group 2, and Gamguk extract (50mg/Kg) and caffeine (20mg/Kg) were orally administered to Group 3 together.

Considering that rodents are nocturnal in nature, sleep time was measured during the week in which SD rats were supposed to sleep. After the oral administration was over, the cage was recorded for 5 hours using a camcorder (Sony Co., Tokyo, Japan) from 10 am to measure the sleep time, and the measurement time was referred to in previous studies. A total of 3 subjects were recorded, one for each group per day, and only one for each cage was placed so as not to be affected by each other. And the illuminance of the space to be measured was kept constant, humidity 50%, temperature 25°C were maintained, and sound insulation was maintained. Sleep pattern and time are determined as sleep state when rats are in a position with their eyes closed and in a prone position for more than 5 minutes using Multi-Channel Stopwatch (Techsys Co. Seoul, Korea). The time from the time point to the end of sleep was summed and measured (FIG. 5).

As a result, as shown in FIG. 6, when caffeine was treated, the sleeping time was reduced to about 16% level compared to the normal control, but it was confirmed that the sleeping time was recovered by about 4 times or more when caffeine and Gamguk extract were treated together. .

The above results confirmed that the extract of Gamguk of the present invention has an effect of pacifying excessive neuronal activity caused by caffeine and at the same time improving sleep disorders.In particular, the effect of inhibiting the neurological activity of caffeine in a short time It indicates that even persistent action can be suppressed. Accordingly, the Gamguk extract of the present invention can be widely used for improving sleep disorders while stabilizing neuronal activity induced by caffeine.

The results of this experiment were expressed as mean ± standard error (S.E.M). After converting the calculated spike values or ratios of each group, an ANOVA Tukey post-test was performed to investigate the differences between groups. When p<0.05, p<0.01, and p<0.001, there were statistically significant differences between groups.

The above description of the present invention is for illustrative purposes only, and those of ordinary skill in the art to which the present invention pertains will be able to understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not limiting. For example, each component described as a single type may be implemented in a distributed manner, and similarly, components described as being distributed may also be implemented in a combined form.

The scope of the present invention is indicated by the claims to be described later, and all changes or modified forms derived from the meaning and scope of the claims and the concept of equivalents thereof should be construed as being included in the scope of the present invention.

Claims (7)

A food composition for improving sleep disorders caused by caffeine, comprising an extract of Gamguk. The method of claim 1,
The extract is one or more solvents selected from the group consisting of water, C ₁ to C ₄ anhydrous or lower alcohol, a mixed solvent of water and lower alcohol, acetone, 1,3-butylene glycol, ethyl acetate, and chloroform. The food composition obtained by extraction. The method of claim 1,
The sleep disorder is caffeine-induced insomnia or circadian rhythm sleep disorders. The method of claim 1,
The food composition will be coffee, food composition. The method of claim 1,
The food composition will be a food additive, food composition. A pharmaceutical composition for preventing and treating sleep disorders caused by caffeine, comprising an extract of Gamguk. The method of claim 6,
The sleep disorder is caffeine-induced insomnia or circadian rhythm sleep disorders, the pharmaceutical composition.

Images